Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

960 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Zhou C, et al. Among authors: girard n. N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870976 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 36815433
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Wakelee H, et al. N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3. N Engl J Med. 2023. PMID: 37272513 Free PMC article. Clinical Trial.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 37589131
Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated EGFR Exon 20 insertion-mutated non-small-cell lung cancer.
Kim TM, Girard N, Leighl NB, Sabari J, Rahhali N, Schioppa CA, Diels J, Sermon J, Chandler C, Kapetanakis V, Jain R, Li T, Sanden SV. Kim TM, et al. Among authors: girard n. Future Oncol. 2024 Mar;20(8):447-458. doi: 10.2217/fon-2023-0620. Epub 2023 Oct 26. Future Oncol. 2024. PMID: 37882460 Free article.
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating EGFR Exon 20 Insertion Mutations.
Christopoulos P, Girard N, Proto C, Soares M, Lopez PG, van der Wekken AJ, Popat S, Diels J, Schioppa CA, Sermon J, Rahhali N, Pick-Lauer C, Adamczyk A, Penton J, Wislez M. Christopoulos P, et al. Among authors: girard n. Cancers (Basel). 2023 Nov 8;15(22):5326. doi: 10.3390/cancers15225326. Cancers (Basel). 2023. PMID: 38001589 Free PMC article.
VTE with Amivantamab plus Chemotherapy in NSCLC. Reply.
Zhou C, Agrawal T, Girard N. Zhou C, et al. Among authors: girard n. N Engl J Med. 2024 Feb 8;390(6):579-580. doi: 10.1056/NEJMc2314937. N Engl J Med. 2024. PMID: 38324503 No abstract available.
960 results